Daniel M. Skovronsky, M.D., Ph.D.

Daniel M. Skovronsky, M.D., Ph.D.

DirectoratEli Lilly & Co· In proxies 2021–2025

Pay in FY2025+41% from the year before

Daniel M. Skovronsky, M.D., Ph.D. was paid $17.8M in FY2025 (Dec), up 41%.

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each Eli Lilly & Co proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Myriad GeneticsPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  2. Eli Lilly & CoPublic company · 5 yr
    • Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs2021 – Present · 5 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Myriad GeneticsDirector · 5 yr on the boardIndependentCompensation and Human Capital, Research and Product Innovation—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?